BioInvent: Key Opinion Leader Highlights BI-1206 Potential
Research Note
2020-07-23
12:50
Redeye reiterates its positive stance on BioInvent following a recent KOL event discussing the potential of lead antibody program BI-1206.
NE
Niklas Elmhammer
Disclosures and disclaimers